You are here:
boceprevir (Victrelis) Naive Patients
Advice
following a full submission
boceprevir (Victrelis®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.
In the pivotal, phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV who were previously untreated increased the proportion of patients with HCV who achieved a sustained virologic response.
Drug Details
| Drug Name: | boceprevir (Victrelis) Naive Patients |
|---|---|
| SMC Drug ID: | 723/11 |
| Manufacturer: | Merck Sharp and Dohme Ltd |
| Indication: | Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated. |
| BNF Category: | |
| Sub Category: | 5.3 Antiviral Drugs |
| Submission Type: | Full submission |
| Status: | Accepted |
| Date Advice Published: | 10 October 2011 |